Detailed Information on Publication Record
2011
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1.
DWYER, Michael, Kamil PARUCH, Marc LABROLI, Carmen ALVAREZ, Kerry KEERTIKAR et. al.Basic information
Original name
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1.
Name in Czech
Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1.
Authors
DWYER, Michael (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor, belonging to the institution), Marc LABROLI (840 United States of America), Carmen ALVAREZ (840 United States of America), Kerry KEERTIKAR (840 United States of America), Cory POKER (840 United States of America), Randall ROSSMAN (840 United States of America), Thierry FISCHMANN (840 United States of America), Jose DUCA (840 United States of America), Vincent MADISON (840 United States of America), David PARRY (840 United States of America), Nicole DAVIS (840 United States of America), Wolfgang SEGHEZZI (840 United States of America), Derek WISWELL (840 United States of America) and Timothy GUZI (840 United States of America)
Edition
Bioorganic & Medicinal Chemistry Letters, Elsevier, 2011, 0960-894X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
10401 Organic chemistry
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 2.554
RIV identification code
RIV/00216224:14310/11:00051795
Organization unit
Faculty of Science
UT WoS
000285544400096
Keywords in English
Kinase CHK1 Pyrazolo[1 5-a]pyrimidine Template
Změněno: 5/3/2012 11:19, Ing. Zdeňka Rašková
Abstract
V originále
The synthesis and hit-to-lead SAR development of a pyrazolo[1,5-a]pyrimidine hit 4 is described leading to a series of potent, selective CHK1 inhibitors such as compound 17r. In the Letter, the further utility of the pyrazolo[1,5-a]pyrimidine template for the development of potent, selective kinase inhibitors is detailed.